ATE378317T1 - Pyridin-derivate als cb2-rezeptor-modulatoren - Google Patents
Pyridin-derivate als cb2-rezeptor-modulatorenInfo
- Publication number
- ATE378317T1 ATE378317T1 AT03750676T AT03750676T ATE378317T1 AT E378317 T1 ATE378317 T1 AT E378317T1 AT 03750676 T AT03750676 T AT 03750676T AT 03750676 T AT03750676 T AT 03750676T AT E378317 T1 ATE378317 T1 AT E378317T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor modulators
- pyridine derivatives
- pyridine
- derivatives
- modulators
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0222493.9A GB0222493D0 (en) | 2002-09-27 | 2002-09-27 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE378317T1 true ATE378317T1 (de) | 2007-11-15 |
Family
ID=9944904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03750676T ATE378317T1 (de) | 2002-09-27 | 2003-09-25 | Pyridin-derivate als cb2-rezeptor-modulatoren |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20060240048A1 (de) |
| EP (1) | EP1565442B1 (de) |
| JP (1) | JP2006503845A (de) |
| KR (1) | KR20050071514A (de) |
| CN (1) | CN1703402A (de) |
| AR (1) | AR041395A1 (de) |
| AT (1) | ATE378317T1 (de) |
| AU (1) | AU2003268907A1 (de) |
| BR (1) | BR0314635A (de) |
| CA (1) | CA2500231A1 (de) |
| DE (1) | DE60317555T2 (de) |
| ES (1) | ES2294313T3 (de) |
| GB (1) | GB0222493D0 (de) |
| IS (1) | IS7809A (de) |
| MA (1) | MA27448A1 (de) |
| MX (1) | MXPA05003263A (de) |
| NO (1) | NO20052028L (de) |
| NZ (1) | NZ538943A (de) |
| PL (1) | PL375990A1 (de) |
| RU (1) | RU2005112752A (de) |
| TW (1) | TW200413321A (de) |
| WO (1) | WO2004029026A1 (de) |
| ZA (1) | ZA200502084B (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2479744A1 (en) | 2002-03-28 | 2003-10-09 | Paul E. Finke | Substituted 2,3-diphenyl pyridines |
| UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| AR043633A1 (es) * | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
| GB0402357D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| GB0402355D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| GB0402356D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| SE0401345D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine as scaffold |
| SE0401342D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| SE0401343D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine N oxide as scaffold |
| ATE412651T1 (de) | 2004-06-09 | 2008-11-15 | Glaxo Group Ltd | Pyrrolopyridinderivate |
| AR055601A1 (es) * | 2005-08-09 | 2007-08-29 | Glaxo Group Ltd | Compuestos derivados de imidazopiridina como ligandos de receptores canabinoides |
| GB0519760D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
| US20090275611A1 (en) * | 2006-04-07 | 2009-11-05 | Boehringer Ingelheim International Gmbh | Compounds Which Modulate The CB2 Receptor |
| KR101114704B1 (ko) * | 2006-10-04 | 2012-03-14 | 에프. 호프만-라 로슈 아게 | Ｃｂ2 수용체 조절제로서 피라진-2-카복스아마이드 유도체 |
| WO2008063625A2 (en) * | 2006-11-20 | 2008-05-29 | Adolor Corporation | Pyridine compounds and methods of their use |
| JP5329437B2 (ja) * | 2007-02-22 | 2013-10-30 | ヘメラス・メディカル・エルエルシー | 大容量の体液濾過装置 |
| BRPI1007202A2 (pt) * | 2009-01-22 | 2016-02-23 | Raqualia Pharma Inc | composto de fórmula (i), composição farmacêutica, método para tratamento de condição mediada pela atividade do receptor cb2 em um indivíduo mamífero e uso de composto de fórmula (i) |
| RU2011143740A (ru) | 2009-03-30 | 2013-05-10 | Астеллас Фарма Инк. | Соединение пиримидина |
| RU2567390C2 (ru) * | 2009-08-24 | 2015-11-10 | Ньюралстем, Инк. | Получение нейростимулирующего пиперазина |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| JP2013048962A (ja) * | 2012-12-12 | 2013-03-14 | Hemerus Medical Llc | 大容量の体液濾過装置 |
| WO2018055640A1 (en) * | 2016-09-22 | 2018-03-29 | Srf Limited | Process for the preparation of haloalkyl derivatives of nicotinic acid |
| EP3814328A1 (de) | 2018-06-27 | 2021-05-05 | F. Hoffmann-La Roche AG | Neuartige azetidin-substituierte pyridin- und pyrazinverbindungen als inhibitoren des cannabinoid-rezeptors 2 |
| CR20200643A (es) * | 2018-06-27 | 2021-05-11 | Eth Zuerich | Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2 |
| CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| WO2020025574A1 (en) | 2018-08-03 | 2020-02-06 | Bayer Aktiengesellschaft | Process for the preparation of 6-(haloalkyl)-2-halo-5-acylpyridines and intermediates for this process |
| EP3666759A1 (de) | 2018-12-10 | 2020-06-17 | Bayer Aktiengesellschaft | Herstellung von 6-halo-2-(haloalkyl)-3-acylpyridinen und zwischenprodukte davon |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
-
2002
- 2002-09-27 GB GBGB0222493.9A patent/GB0222493D0/en not_active Ceased
-
2003
- 2003-09-25 CN CNA038254727A patent/CN1703402A/zh active Pending
- 2003-09-25 KR KR1020057005234A patent/KR20050071514A/ko not_active Withdrawn
- 2003-09-25 DE DE60317555T patent/DE60317555T2/de not_active Expired - Fee Related
- 2003-09-25 US US10/528,613 patent/US20060240048A1/en not_active Abandoned
- 2003-09-25 WO PCT/EP2003/010930 patent/WO2004029026A1/en not_active Ceased
- 2003-09-25 AR ARP030103499A patent/AR041395A1/es not_active Application Discontinuation
- 2003-09-25 PL PL03375990A patent/PL375990A1/xx not_active Application Discontinuation
- 2003-09-25 EP EP03750676A patent/EP1565442B1/de not_active Expired - Lifetime
- 2003-09-25 AT AT03750676T patent/ATE378317T1/de not_active IP Right Cessation
- 2003-09-25 RU RU2005112752/04A patent/RU2005112752A/ru not_active Application Discontinuation
- 2003-09-25 CA CA002500231A patent/CA2500231A1/en not_active Abandoned
- 2003-09-25 AU AU2003268907A patent/AU2003268907A1/en not_active Abandoned
- 2003-09-25 MX MXPA05003263A patent/MXPA05003263A/es unknown
- 2003-09-25 BR BR0314635-9A patent/BR0314635A/pt not_active IP Right Cessation
- 2003-09-25 JP JP2004539056A patent/JP2006503845A/ja not_active Withdrawn
- 2003-09-25 NZ NZ538943A patent/NZ538943A/en unknown
- 2003-09-25 ES ES03750676T patent/ES2294313T3/es not_active Expired - Lifetime
- 2003-09-25 TW TW092126422A patent/TW200413321A/zh unknown
-
2005
- 2005-03-11 ZA ZA200502084A patent/ZA200502084B/en unknown
- 2005-03-28 MA MA28176A patent/MA27448A1/fr unknown
- 2005-04-19 IS IS7809A patent/IS7809A/is unknown
- 2005-04-26 NO NO20052028A patent/NO20052028L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL375990A1 (en) | 2005-12-12 |
| DE60317555T2 (de) | 2008-10-23 |
| ES2294313T3 (es) | 2008-04-01 |
| MXPA05003263A (es) | 2005-07-05 |
| NO20052028L (no) | 2005-06-03 |
| WO2004029026A1 (en) | 2004-04-08 |
| CN1703402A (zh) | 2005-11-30 |
| EP1565442B1 (de) | 2007-11-14 |
| JP2006503845A (ja) | 2006-02-02 |
| DE60317555D1 (de) | 2007-12-27 |
| TW200413321A (en) | 2004-08-01 |
| US20060240048A1 (en) | 2006-10-26 |
| RU2005112752A (ru) | 2006-01-20 |
| KR20050071514A (ko) | 2005-07-07 |
| BR0314635A (pt) | 2005-08-02 |
| MA27448A1 (fr) | 2005-07-01 |
| NZ538943A (en) | 2007-01-26 |
| EP1565442A1 (de) | 2005-08-24 |
| ZA200502084B (en) | 2006-02-22 |
| AR041395A1 (es) | 2005-05-18 |
| GB0222493D0 (en) | 2002-11-06 |
| CA2500231A1 (en) | 2004-04-08 |
| IS7809A (is) | 2005-04-19 |
| AU2003268907A1 (en) | 2004-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60317555D1 (de) | Pyridin-derivate als cb2-rezeptor-modulatoren | |
| ATE497953T1 (de) | Thiazolderivate als modulatoren des cannabinoidrezeptors | |
| DE602004015724D1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
| DE602004024420D1 (de) | Chinazolinderivate als antitumormittel | |
| IS7625A (is) | Nýjar samrunnar imídazól afleiður | |
| ATE384053T1 (de) | Triazolderivate als tachykininrezeptor- antagonisten | |
| IS7939A (is) | Pýrasólpýridín afleiður | |
| DE50304983D1 (de) | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren | |
| DE60330694D1 (de) | Pyrimidopyrimidone als kinaseinhibitoren | |
| DE602007006531D1 (de) | Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren | |
| NO20050654L (no) | Azolidinon-vinyl fusjonerte benzenderivater | |
| ATE370936T1 (de) | Substituierte pyrazin- oder pyridin-derivate als glukokinase-aktivatoren | |
| ATE439357T1 (de) | Indolylderivate als liver-x-rezeptormodulatoren | |
| DE60327767D1 (de) | Tricyclische steroidhormonkernrezeptor-modulatoren | |
| ITMI20030310V0 (it) | Cerniera | |
| NO20051042L (no) | Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer | |
| DE60331931D1 (de) | Cox-2-inhibierende pyridinderivate | |
| ATE518834T1 (de) | 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten | |
| ATE306265T1 (de) | Benzothiazolderivate als adenosin-rezeptor- liganden | |
| DE60316411D1 (de) | Thiazolderivate als npy-rezeptorantagonisten | |
| DE602004014772D1 (de) | Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors | |
| ATE377008T1 (de) | Imidazolderivate als glutamatrezeptorantagonisten | |
| ATE293619T1 (de) | Pyridinderivate als nmda-rezeptorliganden | |
| ATE394372T1 (de) | G-lactamderivate als prostaglandinagonisten | |
| ATE433956T1 (de) | Cannabinoid-rezeptorliganden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |